Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGA: Nivolumab and Trastuzumab with Ipilimumab or FOLFOX in HER2+ Esophagogastric Adenocarcinoma
NCT03409848Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Mar 2018
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in Esophago-Gastric Adenocarcinoma, sponsored by AIO-Studien. Started Mar 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT03409848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409848.